Claudio Gasperini

Summary

Country: Italy

Publications

  1. ncbi request reprint MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a
    C Gasperini
    Department of Neuroscience, S Camillo Forlanini Hospital, Rome, Italy
    Mult Scler 8:119-23. 2002
  2. doi request reprint New oral drugs for multiple sclerosis
    Claudio Gasperini
    Centro Sclerosi Multipla, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Neurol Sci 30:S179-83. 2009
  3. doi request reprint Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies
    Claudio Gasperini
    Multiple Sclerosis Center, S Camillo Forlanini, Neurosciences, Circonvallazione Gianicolense 87, Rome 00152, Italy
    Expert Opin Investig Drugs 22:1243-53. 2013
  4. pmc Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach
    Claudio Gasperini
    Department of Neurosciences, S Camillo Forlanini Hospital, University of Rome Sapienza, Rome, Italy
    Drug Des Devel Ther 6:175-86. 2012
  5. doi request reprint Emerging oral drugs for relapsing-remitting multiple sclerosis
    Claudio Gasperini
    Dipartimento Testa Collo, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Expert Opin Emerg Drugs 16:697-712. 2011
  6. ncbi request reprint Emerging oral drugs for multiple sclerosis
    Claudio Gasperini
    S Camillo Forlanini Hospital, Department of Neuroscience, Viale dell Universita 30, 00185 Rome, Italy
    Expert Opin Emerg Drugs 13:465-77. 2008
  7. pmc Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study
    Emilia Sbardella
    Departments of Neurological Sciences, Sapienza University, Rome, Italy
    BMC Neurol 9:54. 2009
  8. doi request reprint Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis
    Luca Prosperini
    Department of Neurology and Psychiatry, Multiple Sclerosis Centre, S Andrea Hospital, Sapienza University, Rome, Italy
    Mult Scler 18:64-71. 2012
  9. doi request reprint Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis
    Valerio Chiurchi├╣
    Department of Biomedical Sciences, University of Teramo, Teramo, Italy
    Ann Neurol 73:626-36. 2013
  10. ncbi request reprint CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1
    Luca Battistini
    Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Santa Lucia, Rome, Italy
    Blood 101:4775-82. 2003

Collaborators

Detail Information

Publications22

  1. ncbi request reprint MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a
    C Gasperini
    Department of Neuroscience, S Camillo Forlanini Hospital, Rome, Italy
    Mult Scler 8:119-23. 2002
    ..The only parameter that predicted brain volume decrease by 2 years of IFNbeta-1a treatment was the mean volume of enhancing lesions over the 6-month pretreatment period...
  2. doi request reprint New oral drugs for multiple sclerosis
    Claudio Gasperini
    Centro Sclerosi Multipla, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Neurol Sci 30:S179-83. 2009
    ..Several pivotal reports have provided promising results for new oral therapies evaluating the safety and efficacy of new agents including fingolimod, fumaric acid, cladribine, teriflunomide and laquinimod...
  3. doi request reprint Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies
    Claudio Gasperini
    Multiple Sclerosis Center, S Camillo Forlanini, Neurosciences, Circonvallazione Gianicolense 87, Rome 00152, Italy
    Expert Opin Investig Drugs 22:1243-53. 2013
    ..Despite the standard of care for patients with MS is significantly improved in recent years, there is still room for improvement in terms of effectiveness and also compliance...
  4. pmc Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach
    Claudio Gasperini
    Department of Neurosciences, S Camillo Forlanini Hospital, University of Rome Sapienza, Rome, Italy
    Drug Des Devel Ther 6:175-86. 2012
    ..We summarily review the oral compounds in study, focusing on the recent development, approval and the clinical experience with FTY720...
  5. doi request reprint Emerging oral drugs for relapsing-remitting multiple sclerosis
    Claudio Gasperini
    Dipartimento Testa Collo, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Expert Opin Emerg Drugs 16:697-712. 2011
    ..Nevertheless, in clinical practice DMDs or immunosuppressive treatments are frequently associated with suboptimal response in terms of efficacy and several side effects leading to poor patient adherence...
  6. ncbi request reprint Emerging oral drugs for multiple sclerosis
    Claudio Gasperini
    S Camillo Forlanini Hospital, Department of Neuroscience, Viale dell Universita 30, 00185 Rome, Italy
    Expert Opin Emerg Drugs 13:465-77. 2008
    ....
  7. pmc Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study
    Emilia Sbardella
    Departments of Neurological Sciences, Sapienza University, Rome, Italy
    BMC Neurol 9:54. 2009
    ..We aimed to quantify the contribution of NAbs to the sub-optimal response of IFNbeta treatment...
  8. doi request reprint Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis
    Luca Prosperini
    Department of Neurology and Psychiatry, Multiple Sclerosis Centre, S Andrea Hospital, Sapienza University, Rome, Italy
    Mult Scler 18:64-71. 2012
    ..To evaluate whether an escalation approach was more effective in suppressing clinical and magnetic resonance imaging (MRI) activity than switching among immunomodulators in relapsing-remitting multiple sclerosis (RRMS) patients...
  9. doi request reprint Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis
    Valerio Chiurchi├╣
    Department of Biomedical Sciences, University of Teramo, Teramo, Italy
    Ann Neurol 73:626-36. 2013
    ..However, the role of DCs in MS pathogenesis remains poorly understood...
  10. ncbi request reprint CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1
    Luca Battistini
    Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Santa Lucia, Rome, Italy
    Blood 101:4775-82. 2003
    ..In conclusion, our results show that CD8+, but not CD4+, T cells from patients with RRMS in the acute phase of the disease display increased ability to be recruited in inflamed brain venules...
  11. pmc Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets
    Claudio Gasperini
    Department of Neurosciences, S Camillo Forlanini Hospital, Rome, Italy
    Ther Clin Risk Manag 6:391-9. 2010
    ..This paper reviews the new oral emerging treatments and presents the available data about the use of cladribine in MS and the future perspective of its clinical use...
  12. pmc Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis
    Daniela F Angelini
    Neuroimmunology Unit, Fondazione Santa Lucia I R C C S, Rome, Italy
    PLoS Pathog 9:e1003220. 2013
    ..We therefore propose that inability to control EBV infection during inactive MS could set the stage for intracerebral viral reactivation and disease relapse...
  13. ncbi request reprint Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis
    Carlo Pozzilli
    Department of Neurological Sciences, University La Sapienza, Rome, Italy
    J Neurol 249:50-6. 2002
    ..o49 for definition II, by the Wilcoxon-Gehan test). Methylprednisilone combined with IFNbeta-1 b reduces the incidence of neutralizing bodies to in terferon-beta during the first year of treatment in MS patients...
  14. ncbi request reprint Alexithymia in multiple sclerosis: relationship with fatigue and depression
    B Bodini
    Department of Neurological Sciences, Sapienza University of Rome, Italy
    Acta Neurol Scand 118:18-23. 2008
    ....
  15. ncbi request reprint The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study
    C Solaro
    Department of Neurology, P A Micone Hospital, Genova, Italy
    Neurology 63:919-21. 2004
    ..This study underlines the relevance of pain in the clinical history of MS...
  16. ncbi request reprint 'Gender gap' in multiple sclerosis: magnetic resonance imaging evidence
    C Pozzilli
    Department of Neurological Sciences, University La Sapienza, Rome, Italy l it
    Eur J Neurol 10:95-7. 2003
    ..Thus, our data indicate that men with MS are prone to develop less inflammatory, but more destructive lesions than women. This study results provides support for a modulation of the MS pathological changes by gender...
  17. ncbi request reprint A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta
    A Paolillo
    Department of Neurological Sciences, University of Rome La Sapienza, Viale dell Universita 30, 00185 Rome, Italy
    Eur J Neurol 9:645-55. 2002
    ....
  18. ncbi request reprint Relationship between emotional distress in caregivers and health status in persons with multiple sclerosis
    C Pozzilli
    Department of Neurological Sciences, La Sapienza University, Rome, Italy
    Mult Scler 10:442-6. 2004
    ..It suggests that the caregiver is an appropriate and independent target for more focused therapeutic strategies...
  19. pmc Home based management in multiple sclerosis: results of a randomised controlled trial
    C Pozzilli
    Dipartimento di Scienze Neurologiche, Universita La Sapienza, Rome, Italy
    J Neurol Neurosurg Psychiatry 73:250-5. 2002
    ..Home based medical care is a popular alternative to standard hospital care but there is uncertainty about its cost-effectiveness...
  20. ncbi request reprint A one-year study on the pharmacodynamic profile of interferon-beta1a in MS
    F Bagnato
    Department of Neurological Sciences, University La Sapienza, Rome, Italy
    Neurology 58:1409-11. 2002
    ..Predose levels of beta2-MG increased, the significance of which is as yet unclear...
  21. ncbi request reprint Differential diagnosis in multiple sclerosis
    C Gasperini
    Multiple Sclerosis Center, Department of Neuroscience, S. Camillo-Forlanini Hospital, Rome, Italy
    Neurol Sci 22:S93-7. 2001
    ..In this paper, I illustrate the diagnostic work-up that the practicing physician should follow when first confronted by a patient suspected of having MS...
  22. ncbi request reprint Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis
    C Gasperini
    Department of Neurology, Ospedale San Camillo-Forlanini, University La Sapienza, Rome, Italy
    Mult Scler 7:27-31. 2001
    ..This study shows that the use of different observers and MR scanners has only a small influence on the measured brain volume and does not affect the reproducibility of this measurement greatly...